ImmunityBio (IBRX) Income from Non-Controlling Interests (2017 - 2026)
ImmunityBio's (IBRX) quarterly Income from Non-Controlling Interests came in at -$15000.0 in Q1 2026, up 25.0% year-on-year from -$12000.0 in Q1 2025, and down 7.14% on a QoQ basis from -$14000.0 in Q4 2025.
ImmunityBio (IBRX) Income from Non-Controlling Interests (2017 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 10 years of Income from Non-Controlling Interests data on file, last reported at -$15000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests rose 25.0% year-over-year to -$15000.0 in Q1 2026; TTM through Mar 2026 was -$69000.0, a 13.75% increase from a year earlier, with the FY2025 full-year figure at -$74000.0, up 8.64% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$15000.0, down from -$14000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for IBRX reached as high as -$14000.0 in Q4 2025 and fell as low as -$334000.0 in Q2 2023.
- Historically, Income from Non-Controlling Interests has averaged -$92882.4 across 5 years, with a median of -$22000.0 in 2023.
- Across the five-year window, Income from Non-Controlling Interests sank 39.53% in 2023 and surged 94.01% in 2024, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$111000.0 in 2022, then jumped by 80.18% to -$22000.0 in 2023, then increased by 22.73% to -$17000.0 in 2024, then gained by 17.65% to -$14000.0 in 2025, then slipped by 7.14% to -$15000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$15000.0 in Q1 2026, -$14000.0 in Q4 2025, and -$21000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | - |
| 10 | ImmunityBio | 7.15 Bn | 6.77 Bn | 43.97 Mn | -15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15,000.00 |
| Dec 31, 2025 | -14,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Mar 31, 2025 | -20,000.00 |
| Dec 31, 2024 | -17,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | -21,000.00 |
| Dec 31, 2023 | -22,000.00 |
| Sep 30, 2023 | -60,000.00 |
| Jun 30, 2023 | -334,000.00 |
| Mar 31, 2023 | -240,000.00 |
| Dec 31, 2022 | -111,000.00 |
| Sep 30, 2022 | -223,000.00 |
| Jun 30, 2022 | -247,000.00 |
| Mar 31, 2022 | -172,000.00 |
| Dec 31, 2021 | -294,000.00 |
| Sep 30, 2021 | -800,000.00 |
| Jun 30, 2021 | -1.10 Mn |